Dette nettstedet krever at JavaScript er aktivert for å fungere skikkelig. Vennligst endre innstillingene dine eller bruk en annen nettleser for å fortsette.

      

Du forlater nå GSKs nettsider

Denne lenken tar deg til en nettside som ikke tilhører GSK. GSK er ikke ansvarlig for, går ikke god for og aksepterer intet ansvar for informasjon eller meninger på nettsteder til tredjeparter

Fortsett

Tilbake

Introducing JULUCA (dolutegravir/rilpivirine) for your virologically suppressed adult HIV patients1

Watch this short video (2 min 30 s) with Dr Marty St. Clair discussing the resistance profile of JULUCA and the reasons behind pairing DTG with RPV.

Video player requires JavaScript enabled. You can download this video here: http://edgesuite.gskstatic.com/HealthSites/Health/Norway/HCP/MP4/no-juluca-resistance-profile-video.mp4

JULUCA clinical data

Get access to the Sword publication and learn about the clinical data behind JULUCA

   

Get fast facts about Juluca

Download an illustrative pdf with JULUCA prescribing information and highlights of the clinical data

JULUCA is indicated for the treatment of human immunodeficiency virus type 1 (HIV-1) infection in adults who are virologically-suppressed (HIV-1 RNA <50 copies/mL) on a stable antiretroviral regimen for at least six months with no history of virological failure and no known or suspected resistance to any non-nucleoside reverse transcriptase inhibitor or integrase inhibitor.1  

JULUCA is owned by or licensed to the ViiV Healthcare group of companies.
©2018 ViiV Healthcare group of companies or its licensor.